中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
2期
33-34
,共2页
肠易激综合征%腹泻型%枯草杆菌二联活菌肠溶胶囊%马来酸曲美布汀
腸易激綜閤徵%腹瀉型%枯草桿菌二聯活菌腸溶膠囊%馬來痠麯美佈汀
장역격종합정%복사형%고초간균이련활균장용효낭%마래산곡미포정
Irritable bowel syndrome%Diarrhea%Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules%Trimebutine maleate
目的观察枯草杆菌二联活菌肠溶胶囊联合马来酸曲美布汀对腹泻型肠易激综合征的疗效.方法将诊断SS肠易激综合征(IBS)腹泻型的117例患者随机分成3组,其中A组给予枯草杆菌二联活菌肠溶胶囊、马来酸曲美布汀联合治疗;B组单用马来酸曲美布汀;C组单用枯草杆菌二联活菌肠溶胶囊.疗程均为4周,治疗期间均停用其他药物,分别给予治疗前及治疗的第2、4周随访,6、8周末进行症状评价及评分.结果 A组临床总有效率为83.3%,B组临床总有效率为52.3%,C组临床总有效率为40.9%,A组与B组、C组比较,差异均有统计学意义(P<0.01).结论枯草杆菌二联活菌肠溶胶囊联合马来酸曲美布汀治疗腹泻型肠易激综合征具有明显的协同作用,临床疗效确切.
目的觀察枯草桿菌二聯活菌腸溶膠囊聯閤馬來痠麯美佈汀對腹瀉型腸易激綜閤徵的療效.方法將診斷SS腸易激綜閤徵(IBS)腹瀉型的117例患者隨機分成3組,其中A組給予枯草桿菌二聯活菌腸溶膠囊、馬來痠麯美佈汀聯閤治療;B組單用馬來痠麯美佈汀;C組單用枯草桿菌二聯活菌腸溶膠囊.療程均為4週,治療期間均停用其他藥物,分彆給予治療前及治療的第2、4週隨訪,6、8週末進行癥狀評價及評分.結果 A組臨床總有效率為83.3%,B組臨床總有效率為52.3%,C組臨床總有效率為40.9%,A組與B組、C組比較,差異均有統計學意義(P<0.01).結論枯草桿菌二聯活菌腸溶膠囊聯閤馬來痠麯美佈汀治療腹瀉型腸易激綜閤徵具有明顯的協同作用,臨床療效確切.
목적관찰고초간균이련활균장용효낭연합마래산곡미포정대복사형장역격종합정적료효.방법장진단SS장역격종합정(IBS)복사형적117례환자수궤분성3조,기중A조급여고초간균이련활균장용효낭、마래산곡미포정연합치료;B조단용마래산곡미포정;C조단용고초간균이련활균장용효낭.료정균위4주,치료기간균정용기타약물,분별급여치료전급치료적제2、4주수방,6、8주말진행증상평개급평분.결과 A조림상총유효솔위83.3%,B조림상총유효솔위52.3%,C조림상총유효솔위40.9%,A조여B조、C조비교,차이균유통계학의의(P<0.01).결론고초간균이련활균장용효낭연합마래산곡미포정치료복사형장역격종합정구유명현적협동작용,림상료효학절.
Objective To observe the clinical effect of the live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with trimebutine maleate on diarrhea-predominant irritable bowel syndrome treatment. Methods Diagnosed as diarrhea-predominant irritable bowel syndrome (IBS), the 117 patients were randomly divided into 3 groups:A group treated with live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with trimebutine maleate, B group with trimebutine maleate alone, and C group with live combined bacillus subtilis and enterococcus faecium enteric-coated capsules alone.All the patients were on a course of 4 weeks, during which no other medicines were used. Then follow-ups were made before the treatment and in 2 weeks and 4 weeks after the treatment respectively, and obtained were the symptom evaluation and score 6 weeks and 8 weeks later. Results The total clinical effective rates of Group A Group B and Group C were 83.3%, 52.3%, 40.9%respectively. Compared with those of Group B and C, the difference was statistically significant (P<0.01). Conclusion It was proved that live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with trimebutine maleate had significant synergistic effects in treating diarrhea-predominant irritable bowel syndrome in addition to clinical curative effect.